Your session is about to expire
← Back to Search
Baloxavir Marboxil for Flu (Pebblestone Trial)
Pebblestone Trial Summary
This trial tests how well a new flu medicine works in children 1-12 years old.
Pebblestone Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 481 Patients • NCT04141930Pebblestone Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has Baloxavir Marboxil been granted regulatory approval by the FDA?
"The safety of Baloxavir Marboxil was given a rating of 3, signifying there is substantial clinical data available to back up its efficacy and security."
Who is eligible to take part in this clinical trial?
"In order to be admitted, participants must possess an active case of influenza and fall within the 1-11 year age range. The study is currently accepting around 600 individuals."
Is the eligibility criteria for this trial inclusive of individuals over 70 years old?
"This highly specific trial requires that enrollees are between 1 and 11 years old."
Are there slots available for enrollees in this trial?
"The latest information from clinicaltrials.gov confirms that recruitments for this medical trial are ongoing, with the first advertisement having been posted on November 30th 2023 and most recent updates occurring on November 14th 2023."
How many individuals have been recruited for this investigation?
"Affirmative. The information available on clinicaltrials.gov attests that this trial, which was first posted on November 30th 2023, is actively enrolling patients. 600 individuals must be enrolled at two separate medical sites."
Share this study with friends
Copy Link
Messenger